Access cutting-edge pediatric glioma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access pediatric glioma specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pediatric glioma treatment provided free
Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. Unfortunately, some BRAF-altered gliomas can progress or have rebound growth after discontinuation of therapy. Data from BRAFV600E-mutant melanoma has shown potential synergy between MAPK inhibition and anti-programmed cell death 1 (anti-PD1) checkpoint blockad
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Check if you qualify for this pediatric glioma clinical trial in Washington Dc, DC
If you're searching for pediatric glioma treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pediatric glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.